Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412

TGN1412 is a “superagonistic” CD28 monoclonal antibody (IgG4) that caused serious adverse events at its first time in human clinical trial. In the present study, different in vitro methods for detecting and quantifying unwanted pro-inflammatory activity of therapeutic monoclonal antibodies (mAbs) su...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of immunological methods 2010-01, Vol.352 (1), p.1-12
Hauptverfasser:	Findlay, Lucy, Eastwood, David, Stebbings, Richard, Sharp, Giles, Mistry, Yogesh, Ball, Christina, Hood, John, Thorpe, Robin, Poole, Stephen
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal, Humanized Binding, Competitive Biological and medical sciences CD28 Antigens - immunology CD28 Antigens - metabolism Cell Proliferation - drug effects Cells, Cultured Drug Evaluation - methods Enzyme-Linked Immunosorbent Assay Fundamental and applied biological sciences. Psychology Fundamental immunology Humans Immobilised antibody Immunotherapy, Active In Vitro Techniques Leukocytes, Mononuclear - drug effects Leukocytes, Mononuclear - immunology Lymphocyte Activation - drug effects Lymphocyte Activation - immunology Molecular immunology Pro-inflammatory cytokines Recombinant Fusion Proteins - metabolism Techniques TGN1412 Therapeutic monoclonal antibodies Tumor Necrosis Factor-alpha - secretion
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!